Skip to main content
Premium Trial:

Request an Annual Quote

For GWAS, Collaboration is the Future

In the UK, GSK and the Medical Research Council have joined forces to make the most of larger GWAS data sets, reports the UK's Business Weekly. In order to maximize the statistical potential of genome-wide association studies, the two will combine data sets and invest £1 million each over three years to focus on finding the genetic switches for two main diseases, depression and obesity. “We have worked hard to collect and refine our data but we now need to take a bold step forwards and work with others to uncover the new disease targets and genetic variations that are useful to inform drug discovery and development,” says Patrick Vallance, senior vice president Drug Discovery at GSK.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.